Di bawah ada daftar dengan kolom dan profil perusahaan yang subyeknya berkaitan.
Berita Hari Ini Kalbe Farma
Kalbe Farma, Indonesia's largest pharmaceutical company, is set to start marketing its erythropoietin product (also known as EPO) domestically. Starting from mid-2018 Kalbe Farma will produce EPO, one of the raw materials for the production of medicines to treat cancer and kidney disease. The pharmaceutical company will become the first publicly listed company on the Indonesia Stock Exchange that produces EPO.
Indonesia's largest pharmaceutical company, Kalbe Farma, felt the impact of macroeconomic headwinds. The company, one of the largest public pharmaceutical companies in Southeast Asia, today announced its indicative performance (unaudited) for the year 2015. While its net sales grew 3 percent year-on-year (y/y) to IDR 17.4 trillion (approx. USD $1.3 billion), the company's net income fell 4.3 percent (y/y) to IDR 1.98 trillion (approx. USD $147 million). Kalbe Farma's performance in 2015 was plagued by weaker purchasing power in Indonesia and the depreciated rupiah exchange rate.
Salah satu paket stimulus ekonomi selanjutnya dari Pemerintah Indonesia akan berfokus pada meningkatkan produksi dalam negeri bahan baku untuk obat-obatan dan perangkat medis. Saat ini, industri tersebut masih sangat tergantung pada impor bahan baku. Diperkirakan bahwa sekitar 90% dari bahan baku/dasar untuk pembuatan obat-obatan dan perangkat medis perlu diimpor dari luar negeri sehingga menyebabkan tekanan tambahan pada neraca pembayaran Indonesia.
On Tuesday (24/03), Indonesian hospital operator Mitra Keluarga Karyasehat became the second company to list on the Indonesia Stock Exchange (IDX) in 2015. It turned out to be a highly successful initial public offering (IPO) as the company’s shares surged 24.7 percent on its trading debut, reflecting investors’ solid confidence in healthcare stocks. Mitra Keluarga, subsidiary of pharmaceutical company Kalbe Farma, raised IDR 4.4 trillion (USD $341 million), hence constituting the largest IPO since Garuda Indonesia’s IPO in 2011.
Shares of Kalbe Farma, Indonesia’s largest pharmaceutical company, have been under pressure over the past couple of days due to the deaths of two hospital patients after they had taken a medicine manufactured by Kalbe Farma. According to the Indonesian Pharmacy Association (GP Farmasi Indonesia) Buvanest Spinal, an anesthetic, was wrongly packaged and hence did not contain bupivacaine but instead tranexamic acid, which aims to stop or reduce heavy bleeding (usually used during surgery).
What were the important corporate news headlines from Indonesia on Thursday 14 August 2014? Below Indonesia Investments presents the daily market roundup. This includes the following companies and topics: XL Axiata, Telekomunikasi Indonesia (Telkom), Kalbe Farma, Telekomunikasi Seluler, Telkomsel, Golden Agri Resources, Matahari Putra Prima, Loop card, Lippo Group, Hypermarts, the Industry Ministry of Indonesia, technology businesses, and the ASEAN Economic Community (AEC).
Indonesia Investments has updated the company profile of PT Kalbe Farma Tbk. Kalbe Farma is the largest listed pharmaceutical company in Indonesia and Southeast Asia (listed on the Indonesia Stock Exchange/IDX). The company’s main business focus rests on four divisions: prescription pharmaceuticals, consumer health products, nutritionals as well as distribution & logistics. Its a leading provider of “comprehensive healthcare solutions”, from pharmaceuticals, nutrition, health foods and beverages to medical devices, including primary healthcare service.
On Thursday (08/05/2014), the winners of the Investor Awards Best Listed Companies 2014, organized by Investor magazine, were announced. Five companies earned the predicate Top Performing Listed Companies 2014 due to the companies sound fundamental and technical performance (over the year 2013). These were Bank Rakyat Indonesia, Kalbe Farma, Tower Bersama Infrastructure, Pembangunan Perumahan, and Lippo Cikarang. These five companies were selected from a total of 493 listed companies on the Indonesia Stock Exchange (IDX).
Artikel Terbaru Kalbe Farma
Companies active in the pharmaceutical industry of Indonesia need to find strategies to overcome sharp rupiah depreciation. Indonesia’s pharmaceutical industry is still - to a large extent - dependent on the import of raw materials, hence a weakening rupiah raises the costs of imports thus eroding profit margins. Since May 2013, when the US Federal Reserve started to hint at monetary tightening, the US dollar has experienced bullish momentum. Between the May 2013 and July 2015, the rupiah depreciated around 37 percent against the US dollar.
Mitra Keluarga Karyasehat, operator rumah sakit dan unit usaha dari Grup Kalbe, menargetkan untuk meraup Rp 4,2 trilliun dalam penawaran umum perdana (IPO) di Bursa Efek Indonesia (BEI) pada Maret 2015. Perusahaan ini akan menawarkan 261,9 juta saham, setara dengan 18% dari modal ditempatkan dan disetor penuh perseroan. Lima persen dari total saham ini adalah saham baru, sementara 13% adalah saham didivestasi private equity firm Lion Investment Partners.
The benchmark stock index of Indonesia (Jakarta Composite Index, abbreviated IHSG) declined 0.92 percent to 5,136.86 points on the last trading day of the week. Seven of the ten sectorial indices fell, led by the finance sector (-1.66 percent), followed by consumer goods (-1.50 percent) and manufacturing (-1.34 percent). The main reason for this poor performance is that investors are again looking at the true fundamentals of the Indonesian economy instead of optimism about Joko Widodo becoming Indonesia’s seventh president.
